InnovoTEX Inc., a pre-clinical stage oncology therapeutics company, announced on Wednesday that it has named Tarak D Mody, PhD as its new director.
In the new role, Dr Mody is to use his extensive expertise in oncology business development, licensing and in forging strategic alliances with pharma and biotech organisations, to expedite development of the platform.
Dr Mody has served in the biopharmaceutical industry for several decades. Presently, he serves as chief business officer at the Parker Institute for Cancer Immunotherapy (PICI). He earlier worked as vice president of Business Development & Alliance Management at Five Prime Therapeutics. He has 20 years of experience at Pharmacyclics Inc. (now AbbVie, Inc.). He has served as a member of the original scientific team prior to transitioning into business development, where he was instrumental in the multi-asset acquisition from Celera Genomics, which included Bruton's tyrosine kinase (BTK) inhibitor discovery programs. He headed business development and intellectual property at Pharmacyclics.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation